UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver

Hugo Girard, Jean Thibaudeau, Michael H. Court, Louis‐Charles Fortier, Lyne Villeneuve, Patrick Caron, Qin Hao, Lisa L. von Moltke, David J. Greenblatt, Chantal Guillemette – 28 June 2005 – PhIP (2‐amino‐1‐methyl‐6‐phenylimidazo[4,5‐f]pyridine), the most abundant heterocyclic amine in diet, is involved in the etiology of cancer. PhIP and its carcinogenic metabolite N‐hydroxy‐PhIP (N‐OH‐PhIP) are extensively conjugated by UDP‐glucuronosyltransferase (UGTs) with wide variability. This study aimed to determine the genetic influence of UGTs on the hepatic detoxification of this carcinogen.

Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: Results of the HALT‐C cohort

Anna S. F. Lok, Marc G. Ghany, Zachary D. Goodman, Elizabeth C. Wright, Gregory T. Everson, Richard K. Sterling, James E. Everhart, Karen L. Lindsay, Herbert L. Bonkovsky, Adrian M. Di Bisceglie, William M. Lee, Timothy R. Morgan, Jules L. Dienstag, Chihiro Morishima – 28 June 2005 – Knowledge of the presence of cirrhosis is important for the management of patients with chronic hepatitis C (CHC). Most models for predicting cirrhosis were derived from small numbers of patients and included subjective variables or laboratory tests that are not readily available.

Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease

Nicola Villanova, Simona Moscatiello, Stefano Ramilli, Elisabetta Bugianesi, Donatella Magalotti, Ester Vanni, Marco Zoli, Giulio Marchesini – 24 June 2005 – Nonalcoholic fatty liver disease (NAFLD) is consistently associated with features of the metabolic syndrome, a condition carrying a high risk of cardiovascular events. We measured the vasodilatory response of the brachial artery in response to ischemia (a test of endothelial function) (FMV) as well as cardiovascular risk profile in 52 NAFLD cases and 28 age‐ and sex‐matched controls.

Circulatory function and hepatorenal syndrome in cirrhosis

Luis Ruiz‐del‐Arbol, Alberto Monescillo, Carlos Arocena, Paz Valer, Pere Ginès, Víctor Moreira, José María Milicua, Wladimiro Jiménez, Vicente Arroyo – 23 June 2005 – The pathogenic mechanism of hepatorenal syndrome is not well established. We investigated the circulatory function in cirrhosis before and after the development of hepatorenal syndrome.

Critical analysis of the pediatric end‐stage liver disease scoring system: A single center experience

Benjamin L. Shneider, Ezequiel Neimark, Tamara Frankenberg, Lindsay Arnott, Frederick J. Suchy, Sukru Emre – 22 June 2005 – The Pediatric End‐Stage Liver Disease (PELD) scoring system is a new nationally utilized formula developed to provide a continuous numerical assessment of the risk of death in order to allocate livers to children for transplantation.

Mycophenolate mofetil combination therapy improves long‐term outcomes after liver transplantation in patients with and without hepatitis C

Russell H. Wiesner, Jolene S. Shorr, Bettina J. Steffen, Alice H. Chu, Robert D. Gordon, John R. Lake – 22 June 2005 – To evaluate the impact of mycophenolate mofetil (MMF) on long‐term outcomes of tacrolimus and corticosteroids, we analyzed data reported to the Scientific Registry of Transplant Recipients for 11,670 adult patients (3463 with hepatitis C [HCV]) who underwent primary, single‐organ, liver transplantation between 1995 and 2001.

Liver transplantation for chronic hepatitis B with lamivudine‐resistant YMDD mutant using add‐on adefovir dipivoxil plus lamivudine

Chung Mau Lo, Chi Leung Liu, George K. Lau, See Ching Chan, Irene O. Ng, Sheung Tat Fan – 22 June 2005 – Lamivudine treatment in patients with chronic hepatitis B virus (HBV) infection may improve clinical state and suppress viral replication before liver transplantation. Emergence of lamivudine‐resistant YMDD mutant is common. We report the results of liver transplantation in 16 patients with pretransplantation YMDD mutants after receiving lamivudine treatment for a median of 738 days (range, 400‐1799 days).

Subscribe to